AtriCure stockholders approve 1.5 million more shares for 2023 stock incentive plan
At its May 18, 2026 annual meeting, AtriCure stockholders approved raising the share reserve of the 2023 Stock Incentive Plan from 4,500,000 to 6,000,000 shares, and approved a 750,000-share increase to the 2018 Employee Stock Purchase Plan. All nine director nominees were elected, and stockholders ratified Deloitte & Touche LLP as auditor for fiscal 2026. The votes give the company additional equity capacity for employee and director compensation, which can dilute existing shareholders.
Key points
- Stockholders approved a 1,500,000-share increase to the 2023 Stock Incentive Plan, from 4,500,000 to 6,000,000 shares.
- Stockholders approved a 750,000-share increase to the 2018 Employee Stock Purchase Plan (42,064,798 for, 109,893 against).
- All nine director nominees were elected to one-year terms expiring at the 2027 annual meeting.
- Deloitte & Touche LLP was ratified as independent auditor for fiscal year ending December 31, 2026 (43,617,566 for, 2,327,505 against).
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.